Cargando…
The treatment landscape in thyroid cancer: a focus on cabozantinib
Although patients with thyroid cancer generally fare well, there is a subset for which this is not necessarily true. Progress in understanding the molecular aberrations in thyroid cancer has led to a change in the management of these cases. Since 2011, four multikinase inhibitors (MKIs) have been ap...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4547654/ https://www.ncbi.nlm.nih.gov/pubmed/26316818 http://dx.doi.org/10.2147/CMAR.S68373 |